论文部分内容阅读
目的观察卡马西平联合多虑平治疗原发性三叉神经痛的效果。方法选择2013年2月—2016年1月收治的原发性三叉神经痛患者200例,随机分为观察组和对照组各100例。对照组采用卡马西平口服治疗,初始剂量为0.1 g/次,3次/d;最小有效维持剂量为0.6~0.8 g/次,每天剂量不超过1.0 g。观察组采用卡马西平联合多虑平口服治疗,卡马西平初始剂量为0.1 g/次,3次/d;逐渐减少剂量,最小有效维持剂量为0.4~0.6 g,每天剂量不超过0.8 g。多虑平25 mg/次,3次/d;逐渐增加剂量至100~250 mg/d,直到患者疼痛消失。两组均治疗12周。对比两组疗效及治疗期间不良反应发生情况。计量资料比较采用t检验,计数资料比较采用χ~2检验,P<0.05为差异有统计学意义。结果观察组治疗总有效率(94.0%)高于对照组(72.0%)(P<0.05)。观察组不良反应发生率(4.0%)低于对照组(15.0%)(P<0.05)。结论卡马西平联合多虑平治疗原发性三叉神经痛效果显著,而且不良反应小。
Objective To observe the effect of carbamazepine and doxepin in the treatment of primary trigeminal neuralgia. Methods A total of 200 patients with primary trigeminal neuralgia admitted from February 2013 to January 2016 were randomly divided into observation group (n = 100) and control group (n = 100). The control group with carbamazepine oral treatment, the initial dose of 0.1 g / time, 3 times / d; the minimum effective maintenance dose of 0.6 ~ 0.8 g / time, daily dose does not exceed 1.0 g. The observation group was treated with carbamazepine combined with doxepin orally. The initial dose of carbamazepine was 0.1 g / time for 3 times / d. The dose was gradually reduced. The minimum effective maintenance dose was 0.4-0.6 g and the daily dose did not exceed 0.8 g. Doxepin 25 mg / time, 3 times / d; gradually increase the dose to 100 ~ 250 mg / d, until the patient’s pain disappeared. Both groups were treated for 12 weeks. The two groups were compared and the adverse reactions during treatment were compared. Measurement data were compared using t test, count data were compared using χ ~ 2 test, P <0.05 for the difference was statistically significant. Results The total effective rate (94.0%) in observation group was higher than that in control group (72.0%) (P <0.05). The incidence of adverse reactions in the observation group (4.0%) was lower than that in the control group (15.0%) (P <0.05). Conclusion Carbamazepine combined with doxepin treatment of primary trigeminal neuralgia significant effect, and adverse reactions.